Updated: Akero says positive PhIIb data buck the gloomy NASH tide, but questions remain on safety front
In NASH, positive readouts don’t come too often. Yet according to Akero, today is that day.
Akero Therapeutics reported results from its 24-week HARMONY Phase IIb trial bright and early Tuesday, looking at lead candidate and ex-Amgen drug efruxifermin, or EFX, in 128 patients with biopsy-confirmed, pre-cirrhotic NASH. And the study met both its primary endpoint and multiple secondary endpoints.
While investigators also flagged some side effects, Akero said the data set it up for a potential Phase III trial to confirm the drug’s impact on an increasingly prevalent disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.